Kintor Pharmaceutical Limited 9939.HK · Stock Open Kintor Pharmaceutical Limited in new tab
Kintor Pharmaceutical Limited Analysis (9939.HK)
Is Kintor Pharmaceutical Limited a good investment? Kintor Pharmaceutical Limited (9939.HK) is currently trading at 1.74 HKD.
Earnings Schedule: Kintor Pharmaceutical Limited is expected to release its next earnings report on April 1, 2027. The market consensus estimate for Forward EPS is -2.37.
Investor FAQ
Does Kintor Pharmaceutical Limited pay a dividend?
No, it does not currently pay a dividend.
What asset class is Kintor Pharmaceutical Limited?
Kintor Pharmaceutical Limited is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be April 1, 2027. The company currently has a trailing EPS of -0.45.
Company Profile
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours that is in phase I and II clinical trial; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer that is in phase I clinical trial; and GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC) that is in phase I clinical trial. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
Community Discussion